PURPOSE: Trachoma is a conjunctival scarring disease, which is the leading infectious cause of blindness worldwide. Elimination of blinding trachoma is being held back by the high rate of trichiasis recurrence following surgery. There is currently no treatment available to suppress the profibrotic state and reduce recurrence. Although the mechanisms underlying trichiasis development are unknown, the profibrotic phenotype has been linked to matrix metalloproteinase (MMP) expression. Doxycycline, a well-known tetracycline antibiotic, can act as a broad MMP inhibitor and has showed some success in preventing fibrosis in various clinical contexts. The purpose of this work was to assess the antiscarring properties of doxycycline in an in vitro model of trichiasis fibroblast-mediated tissue contraction. METHODS: Primary cultures of fibroblasts were established from conjunctival samples obtained from normal donors or during surgery for trachomatous trichiasis. The effect of doxycycline on matrix contraction was investigated in our standard collagen gel contraction model. Cell morphology and matrix integrity were assessed using confocal reflection microscopy. Quantitative real time polymerase chain reaction and a FRET-based assay were used to measure MMP expression and activity, respectively. RESULTS: Doxycycline treatment successfully suppressed the contractile phenotype of trichiasis fibroblasts, matrix degradation, and significantly altered the expression of MMP1, MMP9, and MMP12 associated with the profibrotic phenotype. CONCLUSIONS: In view of the results presented here and the wider use of doxycycline in clinical settings, we propose that doxycycline might be useful as a treatment to prevent recurrence following trichiasis surgery.
PURPOSE:Trachoma is a conjunctival scarring disease, which is the leading infectious cause of blindness worldwide. Elimination of blinding trachoma is being held back by the high rate of trichiasis recurrence following surgery. There is currently no treatment available to suppress the profibrotic state and reduce recurrence. Although the mechanisms underlying trichiasis development are unknown, the profibrotic phenotype has been linked to matrix metalloproteinase (MMP) expression. Doxycycline, a well-known tetracycline antibiotic, can act as a broad MMP inhibitor and has showed some success in preventing fibrosis in various clinical contexts. The purpose of this work was to assess the antiscarring properties of doxycycline in an in vitro model of trichiasis fibroblast-mediated tissue contraction. METHODS: Primary cultures of fibroblasts were established from conjunctival samples obtained from normal donors or during surgery for trachomatous trichiasis. The effect of doxycycline on matrix contraction was investigated in our standard collagen gel contraction model. Cell morphology and matrix integrity were assessed using confocal reflection microscopy. Quantitative real time polymerase chain reaction and a FRET-based assay were used to measure MMP expression and activity, respectively. RESULTS:Doxycycline treatment successfully suppressed the contractile phenotype of trichiasis fibroblasts, matrix degradation, and significantly altered the expression of MMP1, MMP9, and MMP12 associated with the profibrotic phenotype. CONCLUSIONS: In view of the results presented here and the wider use of doxycycline in clinical settings, we propose that doxycycline might be useful as a treatment to prevent recurrence following trichiasis surgery.
Authors: Tina T L Wong; Charanjit Sethi; Julie T Daniels; G Astrid Limb; Gillian Murphy; Peng T Khaw Journal: Surv Ophthalmol Date: 2002 May-Jun Impact factor: 6.048
Authors: J A Curci; D Mao; D G Bohner; B T Allen; B G Rubin; J M Reilly; G A Sicard; R W Thompson Journal: J Vasc Surg Date: 2000-02 Impact factor: 4.268
Authors: Constance A Cox; Juan Amaral; Rita Salloum; Liliana Guedez; Ted W Reid; Cindy Jaworski; Moly John-Aryankalayil; Ken A Freedman; Mercedes M Campos; Alfredo Martinez; Susan P Becerra; Deborah A Carper Journal: Ophthalmology Date: 2010-06-03 Impact factor: 12.079
Authors: Liang Dan; Yan Shi-long; Lin Miao-li; Li Yong-ping; Ma Hong-jie; Zhang Ying; Wang Xiang-gui Journal: Curr Eye Res Date: 2008-08 Impact factor: 2.424
Authors: Jan H N Lindeman; Hazem Abdul-Hussien; J Hajo van Bockel; Ron Wolterbeek; Robert Kleemann Journal: Circulation Date: 2009-04-13 Impact factor: 29.690
Authors: Cynthia Yu-Wai-Man; Aristides D Tagalakis; Jinhong Meng; Yann Bouremel; Richard M H Lee; Alex Virasami; Stephen L Hart; Peng T Khaw Journal: JAMA Ophthalmol Date: 2017-11-01 Impact factor: 7.389
Authors: Abeer H A Mohamed-Ahmed; Alastair Lockwood; He Li; Maryse Bailly; Peng T Khaw; Steve Brocchini Journal: Invest Ophthalmol Vis Sci Date: 2017-07-01 Impact factor: 4.799
Authors: Cynthia Yu-Wai-Man; Nicholas Owen; Jonathan Lees; Aristides D Tagalakis; Stephen L Hart; Andrew R Webster; Christine A Orengo; Peng T Khaw Journal: Sci Rep Date: 2017-07-17 Impact factor: 4.379
Authors: Cynthia Yu-Wai-Man; Bradley Spencer-Dene; Richard M H Lee; Kim Hutchings; Erika M Lisabeth; Richard Treisman; Maryse Bailly; Scott D Larsen; Richard R Neubig; Peng T Khaw Journal: Sci Rep Date: 2017-03-31 Impact factor: 4.379
Authors: Esmael Habtamu; Tariku Wondie; Sintayehu Aweke; Zerihun Tadesse; Mulat Zerihun; Bizuayehu Gashaw; Chrissy H Roberts; Amir Bedri Kello; David C W Mabey; Saul N Rajak; E Kelly Callahan; David Macleod; Helen A Weiss; Matthew J Burton Journal: Lancet Glob Health Date: 2018-05 Impact factor: 38.927